TABLE 2.
Disc susceptibility testing of E. coli DK and pMOO-32 transconjugants of various E. coli recipient strainsa
| Antimicrobial agent | Zone diameter (mm) and resistance category |
||||||
|---|---|---|---|---|---|---|---|
| E. coli DK | E. coli DH5α | E. coli DH5α TR | E. coli HG | E. coli HG TR | E. coli HC4 | E. coli HC4 TR | |
| AMP | <6 (R) | 30 (S) | <6 (R) | <6 (R) | <6 (R) | 20 (S) | <6 (R) |
| CTX | 10 (R) | 45 (S) | 18 (I) | 35 (S) | 10 (R) | 34 (S) | 13 (R) |
| CAZ | 20 (I) | 45 (S) | 30 (S) | 34 (S) | 20 (I) | 32 (S) | 23 (S) |
| FEP | 19 (R) | 45 (S) | 28 (S) | 28 (S) | 18 (R) | 35 (S) | 24 (I) |
| ETP | 30 (S) | 45 (S) | 44 (S) | 34 (S) | 33 (S) | 36 (S) | 36 (S) |
| ATM | 15 (R) | 45 (S) | 24 (I) | 34 (S) | 15 (R) | 35 (S) | 19 (R) |
| STRb | <6 (R) | 25 (S) | 10 (R) | <6 (R) | <6 (R) | 13 (R) | <6 (R) |
| TOB | 17 (S) | 28 (S) | 26 (S) | <6 (R) | <6 (R) | 18 (S) | 19 (S) |
| NEOb | 8 (R) | 20 (S) | 12 (R) | <6 (R) | <6 (R) | 14 (I) | 8 (R) |
| TETb | <6 (R) | 36 (S) | <6 (R) | <6 (R) | <6 (R) | 30 (S) | <6 (R) |
a
AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; ATM, aztreonam; STR, streptomycin; TOB, tobramycin; NEO, neomycin; TET, tetracycline; TR, pMOO-32 transconjugant. Susceptible (S), intermediate (I), and resistant (R) were determined as defined by CLSI criteria (resistant results are highlighted in bold).
b
Streptomycin and neomycin sensitivities were determined using tobramycin EUCAST interpretation guidelines, and tetracycline sensitivities were determined according to guidelines for Yersinia enterocolitica.